The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EMN 2018 | ASCT remains at the forefront of multiple myeloma therapy
Despite recent advances in drug development, autologous stem cell transplant (ASCT) is still, to date, the most effective treatment for multiple myeloma (MM). Speaking from the 1st European Myeloma Network Meeting (EMN) in Turin, Italy, Vittorio Montefusco, MD, of the IRCCS Foundation, National Cancer Institute of Milan, Milan, Italy, explains why this is the case. Dr Montefusco outlines the benefits of using drugs in combination with ASCT, and highlights how the difference in patient fitness between older and younger populations can influence the course of treatment.
